Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Bailey DB, Raspa M, Bishop E, Mitra D, Wheeler A, Sacco P. Health and economic consequences of Fragile X syndrome for caregivers. J Dev Behav Pediatr. 2012 Nov 1;33(9):705-12.
Dysktra LA, Granger AL. Interactions between the delta agonist SNC80, and the mu agonists, morphine, buprenorphine, and butorphanol in squirrel monkeys. Nida Res Monogr. 2000;180:65.
Gfroerer J, Lessler J, Parsley (Edwards) T. Studies of nonresponse and measurement error in the national household survey on drug abuse. Nida Res Monogr. 1997;167:273-95.